background
data
frequenc
role
respiratori
virus
rv
hospitalacquir
pneumonia
hap
still
scarc
object
assess
proport
rv
impact
outcom
hospitalacquir
pneumonia
hap
intens
care
unit
icu
studi
design
case
hap
retrospect
select
among
patient
underw
screen
rv
multiplex
pcr
mpcr
icu
french
tertiari
care
hospit
may
april
icu
length
stay
inhospit
mortal
compar
four
group
defin
accord
identifi
pathogen
viru
v
virusbacteria
vb
bacteria
b
pathogen
neg
avail
previou
mpcr
retriev
order
assess
possibl
chronic
viral
carriag
result
overal
icu
patient
underw
mpcr
hap
v
vb
b
neg
median
age
year
immunocompromis
influenza
rhinoviru
common
rv
vb
group
higher
mortal
rate
b
v
group
vs
p
significantli
longer
length
stay
day
v
group
day
p
b
group
day
p
among
patient
avail
mpcr
test
viral
hap
seven
neg
eight
posit
correspond
longterm
carriag
communityacquir
virus
discuss
rv
detect
hap
patient
underw
mpcr
two
situat
encount
acut
acquir
viral
infect
ii
longterm
viral
carriag
mostli
rhinoviru
especi
immunocompromis
patient
complic
virusbacteria
coinfect
latter
associ
longer
length
stay
trend
toward
higher
mortal
respiratori
virus
rv
known
constitut
larg
burden
communityacquir
respiratori
infect
regard
nosocomi
infect
rv
exclud
herp
simplex
viru
hsv
cytomegaloviru
cmv
tradit
paid
littl
attent
except
hematopoiet
stem
cell
solid
organ
transplant
recipi
although
hospitalacquir
pneumonia
hap
second
common
nosocomi
infect
develop
countri
associ
high
mortal
morbid
alway
seen
driven
bacteria
role
rv
howev
recent
south
korean
studi
case
hap
relat
viral
infect
bacteri
infect
find
show
nonneglig
role
virus
explain
recent
improv
detect
method
need
explor
inde
improv
sensit
detect
techniqu
multiplex
polymeras
chain
reaction
mpcr
greatli
enhanc
abil
detect
rv
howev
data
frequenc
role
rv
hap
especi
outcom
still
scarc
apart
influenza
respiratori
syncyti
viru
rsv
virus
usual
investig
weak
evid
pathogen
lack
avail
treatment
high
cost
mpcr
test
furthermor
role
viralbacteri
coinfect
still
unclear
pneumonia
investig
use
mpcr
conduct
communityacquir
pneumonia
present
viralbacteri
coinfect
yield
diverg
data
pathogen
prognosi
retrospect
review
case
hap
underw
screen
rv
patient
admit
intens
care
unit
icu
order
estim
proport
hap
associ
rv
bacteria
viralbacteri
coinfect
compar
impact
prognosi
studi
conduct
medic
icu
bichatclaud
bernard
hospit
teach
tertiari
referr
hospit
pari
franc
medic
record
patient
underw
mpcr
assay
rv
icu
stay
may
april
retrospect
review
patient
communityacquir
pneumonia
diagnosi
pneumonia
exclud
adult
patient
diagnos
hap
underw
screen
rv
time
suspect
pneumonia
includ
studi
multipl
episod
hap
occur
patient
first
episod
taken
consider
patient
includ
classifi
one
follow
four
group
accord
microorgan
identifi
specimen
collect
within
h
diagnosi
pneumonia
viru
bacteria
virusbacteria
pathogen
note
use
mpcr
respiratori
viru
screen
icu
bichatclaud
bernard
hospit
systemat
left
physician
discret
use
start
first
limit
immunocompromis
patient
progress
expand
year
compar
characterist
undergo
screen
rv
underw
includ
studi
identifi
total
number
hap
occur
studi
period
icu
use
primari
diagnosi
code
accord
tenth
revis
intern
classif
diseas
clinic
laboratori
data
includ
microbiolog
test
radiolog
find
diagnosi
hap
data
retriev
patient
medic
chart
length
icu
stay
diagnosi
pneumonia
inhospit
mortal
collect
compar
group
order
differenti
hospitalacquir
virus
longterm
viral
shed
patient
least
one
viru
found
avail
mpcr
test
perform
hospit
stay
hap
diagnosi
retriev
definit
detail
supplement
data
patient
enrol
studi
underw
bronchoscopi
bronchoalveolar
lavag
bal
endotrach
aspir
eta
microbiolog
evalu
perform
physician
discret
evalu
may
includ
one
set
blood
cultur
gram
stain
cultur
cultur
histolog
examin
diagnosi
fungu
pcr
diagnosi
cytomegaloviru
cmv
herp
simplex
viru
hsv
eta
bal
fluid
screen
rv
nasopharyng
swab
eta
bal
fluid
rv
test
mpcr
assay
use
anyplextm
ii
detect
kit
seegen
inc
seoul
korea
allow
detect
influenza
b
virus
adenoviru
parainfluenza
viru
type
rsv
type
b
picornaviru
rhinovirus
enterovirus
human
metapneumoviru
human
coronavirus
bocaviru
microorgan
identifi
specimen
collect
within
h
diagnosi
pneumonia
consid
pathogen
patient
characterist
outcom
report
number
percentag
categor
variabl
mean
standard
deviat
sd
median
interquartil
rang
iqr
continu
variabl
data
pathogen
group
display
inhospit
mortal
median
icu
length
stay
hap
diagnosi
patient
discharg
aliv
consid
outcom
interest
compar
viru
bacteria
viru
bacteria
group
kruskalw
test
fisher
exact
test
use
appropri
univari
analysi
miss
data
p
valu
less
consid
statist
signific
statist
analys
conduct
use
stata
softwar
statacorp
colleg
station
texa
usa
among
icu
patient
underw
mpcr
assay
test
rv
studi
period
consid
hap
includ
studi
period
hap
admit
occur
icu
patient
thu
screen
rv
perform
hap
patient
characterist
hap
patient
test
rv
similar
patient
describ
studi
except
immun
statu
patient
test
rv
like
immunocompromis
vs
p
patient
median
age
iqr
year
male
fortyf
patient
consid
immunocompromis
sixtyfour
patient
least
one
chronic
underli
diseas
frequent
diabet
mellitu
structur
lung
diseas
median
length
hospit
stay
prior
hap
diagnosi
day
median
sap
ii
score
admiss
baselin
characterist
list
tabl
least
one
pathogen
identifi
patient
bacteri
infect
observ
patient
bacteri
infect
sole
respiratori
viral
infect
found
patient
viral
infect
sole
viral
bacteri
coinfect
concern
case
among
patient
bacteri
infect
identifi
respiratori
specimen
concomit
posit
blood
cultur
hsv
found
case
fungal
infect
case
pneumocysti
jirovecii
n
aspergillu
speci
n
rv
like
found
immunocompromis
patient
vs
p
distribut
pathogen
identifi
shown
tabl
total
bacteria
identifi
patient
two
three
concomit
bacteria
identifi
patient
respect
nonfer
gramneg
bacilli
enterobacteriacea
mssa
methicillinsensit
staphylococcu
aureu
found
case
respect
overal
rv
identifi
patient
none
patient
infect
one
type
viru
virus
detect
bal
fluid
specimen
eta
among
patient
underw
sole
bronchoscopi
bal
underw
bronchoscopi
bal
eta
two
eta
eleven
patient
also
nasopharyng
swab
patient
median
age
year
iqr
underli
condit
immunocompromis
median
length
hospit
stay
prior
pneumonia
day
iqr
influenza
viru
rhinoviru
two
commonli
identifi
virus
n
viru
virus
rsv
n
parainfluenza
viru
n
bocaviru
n
human
coronaviru
n
human
metapneumoviru
n
adenoviru
n
among
patient
respiratori
virusbacteri
coinfect
three
two
also
present
hsv
fungu
respect
patient
coinfect
significantli
like
autoimmun
diseas
patient
sole
bacteria
vs
p
fifteen
patient
hap
least
one
rv
identifi
mpcr
prior
hap
episod
perform
hospit
stay
fig
prior
mpcr
neg
seven
patient
underw
averag
standard
deviat
sd
day
hap
diagnosi
patient
consid
acquir
rv
hospit
characterist
outcom
shown
supplementari
tabl
five
case
occur
icu
ventil
patient
two
nonventil
patient
longterm
care
facil
identifi
virus
rsv
n
parainfluenza
n
metapneumoviru
n
influenza
n
case
viru
infect
group
case
among
seven
patient
identifi
hand
eight
patient
prior
posit
mpcr
averag
sd
day
hap
diagnosi
viru
identifi
time
hap
diagnosi
patient
immunocompromis
consid
longterm
carrier
infect
commun
identifi
virus
rhinoviru
n
influenza
n
eight
case
coinfect
hap
viral
bacteri
n
viralhsvbacteri
n
viralbacterialaspergillu
n
viralhsv
n
suggest
potenti
role
rv
occurr
bacteri
vap
immunocompromis
patient
inhospit
mortal
rate
mortal
rate
includ
patient
respect
median
iqr
icu
length
stay
hap
diagnosi
day
patient
aliv
discharg
mortal
rate
higher
coinfect
virusbacteria
group
bacteria
viru
group
differ
reach
statist
signific
vs
p
inhospit
mortal
vs
p
mortal
among
patient
aliv
hospit
discharg
virusbacteria
coinfect
group
significantli
longer
length
stay
day
viru
group
day
p
bacteria
group
day
p
retrospect
studi
conduct
two
year
one
teach
tertiari
referr
hospit
franc
rv
identifi
hap
patient
admit
icu
underw
respiratori
mpcr
test
influenza
viru
rhinoviru
rsv
commonli
identifi
virus
patient
concern
viral
hap
like
immunocompromis
bacteri
hap
patient
virusbacteria
coinfect
higher
mortal
although
reach
statist
signific
longer
length
stay
icu
bacteria
viru
group
result
regard
proport
natur
rv
found
consist
present
hong
et
al
singlecent
studi
case
sever
hap
seoul
south
korea
twoyear
period
studi
immunocompromis
patient
ventil
rv
identifi
case
predomin
rsv
parainfluenza
viru
rhinoviru
howev
unlik
hong
et
al
virusbacteria
group
studi
present
longer
icu
length
stay
trend
higher
mortal
rate
viru
bacteria
group
hong
et
al
studi
contrari
studi
patient
underw
bal
fluid
eta
argu
favor
activ
role
patient
bal
perform
rv
diagnos
bal
fluid
test
patient
communityacquir
pneumonia
previou
studi
report
clinic
interact
influenza
pneumonia
aureu
major
contributor
influenza
mortal
becom
clear
similar
interact
may
occur
rv
includ
rsv
human
metapneumoviru
possibl
rhinoviru
parainfluenza
viru
howev
clinic
evid
prospect
studi
role
coinfect
sever
somewhat
conflict
studi
underlin
eight
hap
case
longterm
shed
communityacquir
virus
involv
immunocompromis
patient
coinfect
pathogen
shed
rhinovirus
week
uncommon
even
immunocompet
individu
especi
patient
immunodefici
chronic
rhinoviru
carriag
long
month
document
signific
rhinoviru
detect
respiratori
specimen
pneumonia
patient
subject
debat
find
demonstr
rhinoviru
infect
alter
respiratori
microbiom
may
precipit
secondari
bacteri
infect
patient
copd
found
high
rate
proven
nosocomi
hap
patient
underw
prior
rv
screen
hospit
stay
viru
distribut
viralbacteri
coinfect
rate
patient
prognosi
differ
greatli
longterm
viru
shed
case
find
support
possibl
nosocomi
transmiss
variou
rv
influenza
rsv
debilit
patient
prolong
hospit
highlight
need
infect
control
measur
target
health
care
personnel
famili
member
control
hospit
transmiss
sever
limit
work
howev
acknowledg
first
studi
singlecent
retrospect
second
studi
period
mpcr
test
rv
systemat
icu
left
instead
clinician
discret
may
led
select
bia
underestim
total
number
case
hap
admit
patient
icu
occur
icu
tri
overcom
issu
estim
total
number
hap
studi
period
compar
characterist
patient
hap
underw
rv
screen
group
patient
underw
rv
screen
frequent
immunocompromis
third
delay
tradit
use
definit
nosocomi
case
deriv
data
concern
bacteria
delay
may
appropri
rv
incub
shed
data
still
partial
popul
differ
one
viru
anoth
author
agre
median
delay
symptom
day
rv
use
previou
rv
test
done
hap
diagnosi
avail
tri
overcom
issu
final
studi
design
prevent
assess
pathogen
role
rv
howev
fact
rv
obtain
bal
fluid
eta
argu
favor
activ
role
conclus
set
rv
test
twothird
patient
mostli
immunocompromis
admit
hap
hap
occur
icu
rv
identifi
respiratori
virusbacteri
coinfect
latter
seem
associ
poorer
outcom
compar
bacteria
viru
pneumonia
rv
found
hap
could
divid
two
categori
communityacquir
virus
chronic
shed
ie
mainli
rhinoviru
immunocompromis
patient
associ
microorgan
time
hap
ii
hospitalacquir
virus
rsv
parainfluenza
influenza
human
metapneumoviru
debilit
patient
prolong
hospit
retrospect
data
demonstr
causal
relationship
viral
shed
outcom
emphas
need
systemat
prospect
studi
assess
tempor
consequ
viral
infect
viralbacteri
coinfect
current
work
receiv
fund
author
declar
commerci
associ
might
pose
conflict
interest
need
inform
consent
waiv
view
retrospect
observ
natur
studi
intervent
perform
studi
conduct
agreement
french
regul
privaci
data
collect
treatment
approv
advisori
committe
inform
process
research
cctir
author
french
data
protect
author
cnil
declar
local
ethic
committe
